Introduction
============

COPD is a common disease of respiratory system, which is characterized by non-fully reversible airflow obstruction. Acute exacerbations of COPD are important drivers of mortality and reduced quality of life in COPD patients and are the second most common reason for emergency hospital admission. According to a research published by the World Health Organization,[@b1-ppa-10-1197] COPD has become the fourth leading cause of mortality in the US. It is estimated to become the fifth leading cause of disease burden in 2020. In the People's Republic of China, the prevalence of COPD has been estimated at 8.2% among people aged 40 years.[@b2-ppa-10-1197] COPD has thus become an important global health problem.

In order to administrate COPD effectively, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates its guidelines for diagnosis, management, and prevention every year.[@b3-ppa-10-1197] The Chinese version of COPD guidelines[@b4-ppa-10-1197] is formulated based on the GOLD guidelines. As an important part of the management of stable COPD, the Chinese guidelines recommend the pharmacotherapy of patients be monitored closely, especially the medication adherence. Although the acute exacerbations of COPD are potentially preventable by suitable drug, it is very difficult for the patients to follow the prescribed regimens. There are many patients with COPD who cannot take drugs as prescribed or visit their physician.[@b5-ppa-10-1197],[@b6-ppa-10-1197]

Some systematic reviews have demonstrated that the pharmaceutical care may improve the health outcomes of patients with cardiovascular diseases[@b7-ppa-10-1197] and diabetes mellitus.[@b8-ppa-10-1197] However, in the People's Republic of China, treatment for COPD is mainly provided by doctors or nurses, while clinical pharmacist involved occasionally. It was not until 2007 that the clinical pharmacy began to attain long-term development. In the pharmaceutical affairs management of medical institutions, five full-time clinical pharmacists are indispensable. Now, the roles of pharmacists have been expanded from dispensing prescriptions to providing pharmaceutical services to patients; these services include managing medication therapy, distributing educational materials, and monitoring the adverse drug reaction (ADR). COPD has been described as requiring 10% medication and 90% education. To the best of our knowledge, few well-designed clinical trials in the Zhejiang Province of the People's Republic of China have been reported to evaluate the effectiveness of pharmacist-managed clinic (PMC) on medication adherence and health-related quality of life. The aim of this prospective randomized controlled study was to assess the impact of PMC on medication adherence and health-related quality of life in COPD patients.

Methods
=======

Design and setting
------------------

We conducted a prospective randomized controlled study between January 2015 and December 2015. Patients were recruited from Tongde Hospital of Zhejiang Province, which is located in the Hangzhou City of the Zhejiang Province.

Inclusion criteria for patients included 1) age ≥35 years, 2) diagnosis of COPD, 3) regular visit to the pharmacist, 4) no previous diagnosis of uncontrolled psychiatric disease, and 5) no previous diagnosis of severe liver or kidney disease. Patients who were pregnant or analphabetic were excluded. Eligible patients were randomly assigned to either the PMC group or the control group. The randomization codes were generated by computer, and the clinical pharmacist was blinded to it.

In accordance with the GOLD guidelines, the patient's adherence to maintenance therapy and the scores of St George's Respiratory Questionnaire (SGRQ) were chosen as primary outcomes. Secondary outcomes were the acute exacerbation rate, hospitalization rate due to acute exacerbation, and smoking behavior. Adherence was assessed by medication refill adherence (MRA)[@b9-ppa-10-1197],[@b10-ppa-10-1197] score. The MRA score was calculated by the formula: the number of participation days/total number of days; the number of participation days was the period from the beginning date of the study to the date of second clinic visit. If the MRA score was ≥80, the patient was considered adherent.[@b11-ppa-10-1197] The MRA was periodically assessed every 12 months. The SGRQ score is a supervised, self-managed measure, designed specifically for patients with chronic airways disease. The SGRQ has been validated to evaluate the health impairment and responsiveness to therapy in patients with chronic airflow limitation. It has 50 items, divided into three domains: impacts, activities, and symptoms.[@b12-ppa-10-1197] For each domain, the score is from 0 to 100. The lowest score indicated that there was no effect on life completely, and a score of 100 indicated the poorest respiratory health of the patient. A change in the mean score of 4 units has been validated as a clinically significant threshold.[@b13-ppa-10-1197],[@b14-ppa-10-1197] The SGRQ score was periodically reassessed every 6 months.

The smoking status of patients was assessed through a questionnaire at the beginning and the end of this study, which included the following questions: Did you ever smoke?; How long did you smoke?; How many cigarettes do you smoke every day?; Do you still smoke now?; Are you trying to quit?; and Why did you cannot quit smoke?

Ethical approval
----------------

After approval by the research review committee from Tongde Hospital of Zhejiang Province, and written informed patient consent was obtained, we began to design the study.

Pharmacist-managed clinic
-------------------------

To maximize the efficacy and minimize the adverse drug events, the first PMC in the Zhejiang Province was established for respiratory therapy at Tongde Hospital of Zhejiang Province in January 2015. The PMC was opening on Wednesday every week. The pharmacist was mainly responsible for individualized education, and developing a comprehensive pharmaceutical care program. The patients in the control group received the usual care delivered by the doctor, but did not receive prescription services by the clinical pharmacist.

Patients in the PMC group were individually educated. At first, the pharmacist discussed with the patients about the definition of COPD, pathophysiology of the disease, the importance of medication adherence, and the importance of smoking cessation. Then, the pharmacist taught the patients on how to take the prescribed drugs and use the respiratory devices effectively, explained the possible ADR, the possible effect of drug combination, the importance of a well-balanced diet with sufficient intake of fresh fruits and vegetables, and the necessity of timely follow-up by physicians. At last, the pharmacist shared his phone number for the patients to consult conveniently. In order to help the patients understand easily the education plan, the pharmacist prepared many drug education materials,[@b14-ppa-10-1197]--[@b16-ppa-10-1197] especially on how to use the inhaled device, and the patients were allowed to take it to their home. During telephone or network (eg, WeChat) counseling, the pharmacist asked the patients about the effect of medication, explained the examination results, the possible ADR, and reminded when the patients should visit their doctor.

All of the patient's data including sex, age, diagnosis, and drugs used were entered into SPSS Version 19.0 (IBM Corporation, Armonk, NY, USA) for statistical analysis. The characteristics of patients in the PMC group and the control group were compared using chi-square tests. A *P*-value of \<0.05 was considered statistically significant.

Results
=======

During the 12 months of the study, 499 patients were prescreened, of whom 336 were found eligible. Sixty-one percent (n=244) of patients agreed to participate, and were assigned randomly to the PMC group (n=122) or the control group (n=122). Almost 93% (n=227) of patients completed this study. The flow chart of inclusion and exclusion of patients is shown in [Figure 1](#f1-ppa-10-1197){ref-type="fig"}.

There were similar clinical characteristics and socio-demographics between the study participants at baseline ([Table 1](#t1-ppa-10-1197){ref-type="table"}). Most patients were elderly, females, married, and of low educational status. Mean age of the study population was 64.2±14.2 years in the PMC group and 64.6±14.5 years in the control group. More than half of the patients were found to have different comorbidities, such as diabetes and hypertension. The treatment medications were similar between two groups. Most of the patients were suffering from moderate or severe COPD, with a mean forced expiratory volume in 1 second/forced vital capacity of 54%. There was no significant difference in the number of hospital admissions at baseline between the two groups.

During the study, the patients in the PMC group and the control group were offered appropriate treatment medications ([Table 2](#t2-ppa-10-1197){ref-type="table"}). At the baseline, mean MRA scores were 78.8±12.3 in the PMC group and 77.4±12.2 in the control group. After the trial, a significantly greater MRA scores in the PMC group were detected (93.1±14.2 vs 78.8±12.3, *P*\<0.01), compared with the baseline. Additionally, when compared with the control group, there was a significant increase of patients whose MRA scores was ≥80 in the PMC group (83.3% vs 51.3%, *P*\<0.01; [Table 3](#t3-ppa-10-1197){ref-type="table"}).

At the baseline, the patients in both the PMC group and the control group were found to have approximately similar scores in SGRQ (50.9±4.7 vs 50.6±4.6, *P*=0.949). After 12 months, the total SGRQ scores improved significantly after the PMC intervention (42.7±3.2 vs 52.4±5.2, *P*\<0.05), and the scores of the domains of symptoms, activities, and impacts in the PMC group were significantly improved, as shown in [Table 4](#t4-ppa-10-1197){ref-type="table"}. The best improvement was noted in the impacts domain (30.8±2.4 vs 43.2±5.4, *P*\<0.05).

During the study, there were 51 independent acute exacerbations reported. Compared with 16 in the PMC group, 35 acute exacerbations were observed in the control group. Any exacerbation requiring an emergency department visit or hospitalization was regarded as severe, and there were significantly lower number of patients in the PMC group who had a severe exacerbation (14 vs 28, *P*=0.024). In addition, there were fewer hospitalizations in the PMC group (11 vs 35, *P*=0.015). At the beginning of this study, \~74% of patients self-reported to smoke, but after the trial, 83 (71%) patients in the PMC group and 59 (52.2%) patients in the control group quit smoking, as shown in [Table 5](#t5-ppa-10-1197){ref-type="table"}.

Discussion
==========

In this study, we assessed the effectiveness of PMC in 244 patients with COPD. The main outcomes were selected based on GOLD guidelines and the disease management. The PMC significantly improved medication adherence, and scores of SGRQ and its subscales (symptoms, activities, and impacts), and decreased severe exacerbation and hos-pitalization rate.

Based on our study data, a significant difference between the two groups in medication adherence after 12 months was noted, which was most likely attributed to the intensive education received from a clinical pharmacist by the PMC group. This is consistent with a 12-month study of Khdour et al[@b10-ppa-10-1197] in Northern Ireland, as the findings showed that clinical pharmacist-led education for patients with COPD led to a significant improvement in medication adherence. Therefore, positive health education can improve medication adherence of patients with COPD. A clinical pharmacist is well placed in the health care team to act as a link between the physicians and the patients.

With progression, COPD undoubtedly affects the ability of patients to perform normal daily activities, thereby affecting their quality of life.[@b17-ppa-10-1197] As shown in [Table 4](#t4-ppa-10-1197){ref-type="table"}, patients demonstrated a similar SGRQ scores at the baseline; however, SGRQ scores in the PMC group improved significantly after the trial. The findings of this present study on improved SGRQ scores in patients with COPD were inconsistent with those of Jordan et al;[@b18-ppa-10-1197] for instance, the baseline mean scores on SGRQ for the patients in Jordan's research were 36.8, which indicated that the patients may have had a good health status. In our study, the mean score on SGRQ was 50.9; therefore, the patients have had a poor quality of life, so there was a bigger margin for the patients to improve.

The reduction in severe exacerbations and hospitalization rate was another significant improvement in the present study. Since acute exacerbation of COPD can not only destroy health status, but also fasten the progression of disease,[@b19-ppa-10-1197] it was an important treatment target for pharmacist intervention.[@b20-ppa-10-1197] Some study demonstrated an education plan for reduction in hospitalization rate,[@b21-ppa-10-1197] but the researchers emphasized usage of antibiotic and corticosteroid besides pharmacist interventions. In this present clinical trial, the reduction in hospital admissions may be attributable to the reduction in acute exacerbation.

The People's Republic of China has been the world's largest cigarette consumer and producer. It was directly beneficial for a patient to quit smoking, During this study, the motivation for smoking cessation for people with mild COPD was not strong, while the smoking cessation methods based on PMC intervention were effective for patients with moderate and severe COPD.

Limitations
===========

While the present study has a number of methodological strengths, it has several limitations. This study utilized data from a single-center and was performed for a short term; therefore, our patients may not represent the general population of patients with COPD. Furthermore, there was not a gold standard to measure adherence; some methods are useful in daily practice (fast, easy, and cheap to apply), but may overestimate adherence.[@b22-ppa-10-1197] And because some clinical trials are often accepted more frequently for motivating patients, the selection bias may not be fully excluded, which may affect the results.

Conclusion
==========

This study was demonstrated to evaluate the impact of PMC on a wide range of clinical outcomes in patients with COPD. Both primary outcomes, that is, medication adherence and SGRQ scores on symptom and impact, were significantly improved in the PMC group. A trend toward reduction in severe exacerbations, hospitalization rate, and smoking status was also observed. To improve health-related quality of life in patients with COPD, our study clearly demonstrated the effectiveness of implementing a PMC in the People's Republic of China. Clinical pharmacist can be a good support to the doctor in the management of patients with COPD.
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###### 

Patient demographics and clinical characteristics at baseline

  Demographic                                      PMC group (n=114)   Control group (n=113)   *P*-value
  ------------------------------------------------ ------------------- ----------------------- -----------
  Age, mean ± SD (range) (years)                   64.2±14.2           64.6±14.5               0.178
  Sex, n (%)                                                                                   0.043
   Male                                            44 (38.6)           42 (37.1)               
   Female                                          70 (61.4)           71 (62.8)               
  Mean body mass index (SD) (kg/m^2^)              27.9±1.5            28.1±1.8                0.637
  Current smokers, n (%)                           85 (74.5)           84 (74.3)               0.949
  Education, n (%)                                                                             0.825
   High (university)                               35 (30.7)           32 (28.3)               
   Low                                             79 (69.3)           81 (71.6)               
  Marital status, n (%)                                                                        0.924
   Married                                         112 (98.2)          112 (99.1)              
   Other                                           2 (1.7)             1 (0.8)                 
  Living arrangements, n (%)                                                                   0.982
   Alone                                           22 (19.3)           22 (19.4)               
   Not alone                                       92 (80.7)           91 (80.5)               
  FEV~1~, mean ± SD                                                                            0.815
   % predicted                                     55.4±15.7           54.7±14.9               
   FEV~1~/FVC                                      51.5±9.2            50.8±8.8                
  Duration of COPD, mean ± SD (years)              11.5±9.3            10.8±9.1                0.842
  Number of COPD medications, mean ± SD            6.4±1.0             6.2±1.0                 0.904
  Number of hospital admissions (last 12 months)   73                  71                      0.957
  Comorbid conditions, n (%)                       84 (73.6)           85 (75.2)               0.822

**Abbreviations:** PMC, pharmacist-managed clinic; SD, standard deviation; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity.

###### 

Prescribed medications for COPD in the PMC and control group patients

  Prescribed medication    Baseline    12-month treatment               
  ------------------------ ----------- -------------------- ----------- -----------
  SABA                     55 (45.0)   54 (44.2)            51 (44.7)   49 (43.3)
  LABA/ICS                 58 (47.5)   50 (40.9)            68 (59.6)   64 (56.6)
  LABA                     14 (11.4)   15 (12.3)            17 (14.9)   16 (14.2)
  LAMA                     63 (51.6)   62 (50.8)            84 (73.6)   81 (71.6)
  Oral steroids            7 (5.7)     9 (7.4)              8 (7.0)     5 (4.4)
  Anticholinergic agents   32 (26.2)   35 (28.6)            37 (32.4)   38 (33.6)
  Xanthines                22 (18.0)   25 (20.4)            24 (21.0)   25 (19.4)
  *P*-value                0.74                             0.63        

**Abbreviations:** PMC, pharmacist-managed clinic; SABA, short-acting β~2~ agonist; LABA, long-acting β~2~ agonist; ICS, inhaled corticosteroid; LAMA, long-acting muscarinic antagonist.

###### 

Medication adherence in the PMC and control group over the 12-month assessment period

  Adherence to maintenance medication   PMC group    Control group   *P*-value
  ------------------------------------- ------------ --------------- -----------
  MRA score, mean ± SD                                               
   Baseline                             78.8±12.3    77.4±12.2       0.798
   12-month intervention                93.1±14.2    83.2±12.7       0.003
  No of patients with MRA ≥80, n (%)                                 
   Baseline                             63           61              0.904
   12-month intervention                95 (83.3%)   58 (51.3%)      0.002

**Abbreviations:** PMC, pharmacist-managed clinic; MRA, medication refill adherence; SD, standard deviation.

###### 

Changes in SGRQ scores at different time assessments

  SGRQ scores                     PMC group, mean ± SD   Control group, mean ± SD   *P*-value
  ------------------------------- ---------------------- -------------------------- -----------
  Total score                                                                       
   Baseline                       50.9±4.7               50.6±4.6                   0.949
   After 6 months of treatment    47.2±4.6               49.2±4.4                   0.618
   After 12 months of treatment   42.7±3.2               52.4±5.2                   0.024
  Symptoms                                                                          
   Baseline                       47.9±4.4               47.4±4.2                   0.924
   After 6 months of treatment    40.2±2.7               46.8±4.5                   0.227
   After 12 months of treatment   38.2±2.2               44.2±3.8                   0.028
  Activities                                                                        
   Baseline                       53.2±4.9               54.6±4.6                   0.835
   After 6 months of treatment    47.6±3.2               56.6±4.7                   0.427
   After 12 months of treatment   42.3±2.5               50.2±2.7                   0.025
  Impacts                                                                           
   Baseline                       43.2±5.4               44.6±5.1                   0.822
   After 6 months of treatment    35.7±2.9               45.8±5.5                   0.424
   After 12 months of treatment   30.8±2.4               42.8±2.3                   0.024

**Abbreviations:** SGRQ, St George's Respiratory Questionnaire; PMC, pharmacist-managed clinic; SD, standard deviation.

###### 

Severe exacerbations, hospitalizations, and smoking status over the 12 months

  Severe exacerbations, hospitalizations, and smoking status   PMC group, n=114   Control group, n=113   *P*-value
  ------------------------------------------------------------ ------------------ ---------------------- -----------
  Severe exacerbations                                                                                   
   Patients with event, n (%)                                  14 (12.2)          28 (24.7)              0.024
   Total events (n)                                            16                 35                     
  Hospitalizations                                                                                       
   Patients with event, n (%)                                  9 (7.8)            24 (21.2)              0.015
   Total hospitalizations (n)                                  11                 35                     
   Duration of hospitalization, mean ± SD (days)               8.1±2.2            14.2±2.8               0.042
  Current smokers                                                                                        
   After 12 months, n (%)                                      4 (3.5)            25 (22.1)              0.022
   Quit smoking, n (%)                                         81 (71.0)          59 (52.2)              

**Note:** Exacerbations requiring an emergency department visit or hospitalization were regarded as severe.

**Abbreviations:** PMC, pharmacist-managed clinic; SD, standard deviation.
